2. Epogen/Aranesp - Top 10 Warnings and Recalls

Drug: Epogen/Aranesp

2006 sales: 4.1 B/$2.5 B

Manufacturer: Amgen

Safety concern: “black box;” heart and vascular problems at higher doses

Related Articles:
> Analyst: Anemia drug warnings 'not bad'. Report
> Amgen income hammered as anemia drug use drops. Report
> Amgen, J&J win a round in anemia controversy. Report
> Amgen discusses the future with analysts. Report
> New rules limit use of anemia drugs. Report
> Amgen stock slips as anemia drug concerns rise. Report
> New study points to danger of anemia drug. Report

2. Epogen/Aranesp - Top 10 Warnings and Recalls

Suggested Articles

Companies considering this avenue must think through potential implications despite the obvious attraction of early access for patients.

BD says a $1.2 billion investment in its pre-filled syringe business will add surge capacity needed to meet demand in future pandemics.

Ad Environment Matters for Message Receptivity